Bedside Measures of Frailty and Cognitive Function Correlate with Sarcopenia in Patients with Cirrhosis.


Journal

Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782

Informations de publication

Date de publication:
12 2019
Historique:
received: 01 10 2018
accepted: 02 07 2019
pubmed: 12 7 2019
medline: 23 6 2020
entrez: 12 7 2019
Statut: ppublish

Résumé

Frailty and sarcopenia are associated with mortality and poor outcomes among patients with cirrhosis. Frailty is multifactorial but due in part to sarcopenia and cognitive dysfunction. Data are limited regarding the correlation of bedside frailty and cognitive function measures with sarcopenia. To evaluate the correlations between frailty measures and muscle indices from computed tomography (CT). We prospectively enrolled 106 patients with clinically compensated cirrhosis (and no prior hepatic encephalopathy). All patients underwent CT scan and cognitive testing (via inhibitory control test, ICT), and were subject to hand grip, 30-s chair stands, mid-arm muscle area (MAMA), and a four-question algorithm based on the Sickness Impact Profile (SIP) predictive of minimal HE. We evaluated Spearman correlations between all measures as well as the sensitivity and specificity of each measure for falls. In total, 106 (35.3%) patients (55 men) had CT scans to measure skeletal muscle area and quality. Hand grip correlated strongly with skeletal muscle area (correlation coefficient 0.64, p < 0.001) and mildly with ICT performance (0.34, p = 0.002). However, for women, the strongest correlation with hand grip was ICT performance (0.60, p < 0.001). Chair stand performance correlated best with SIP (correlation coefficient - 0.35, p < 0.001). MAMA was not correlated with CT-based muscle indices among women but was for men. Poor chair stand performance (< 10/30-s) had a sensitivity/specificity for falls of 73%/54%; low muscle radiation attenuation (density) was 40%/80% sensitive/specific. Bedside measures of physical function, muscle bulk, and cognitive performance are correlated with CT-based muscle measures. Bedside measures of frailty may provide an advantage over sarcopenia for outcome assessment that should be confirmed prospectively.

Sections du résumé

BACKGROUND
Frailty and sarcopenia are associated with mortality and poor outcomes among patients with cirrhosis. Frailty is multifactorial but due in part to sarcopenia and cognitive dysfunction. Data are limited regarding the correlation of bedside frailty and cognitive function measures with sarcopenia.
AIMS
To evaluate the correlations between frailty measures and muscle indices from computed tomography (CT).
METHODS
We prospectively enrolled 106 patients with clinically compensated cirrhosis (and no prior hepatic encephalopathy). All patients underwent CT scan and cognitive testing (via inhibitory control test, ICT), and were subject to hand grip, 30-s chair stands, mid-arm muscle area (MAMA), and a four-question algorithm based on the Sickness Impact Profile (SIP) predictive of minimal HE. We evaluated Spearman correlations between all measures as well as the sensitivity and specificity of each measure for falls.
RESULTS
In total, 106 (35.3%) patients (55 men) had CT scans to measure skeletal muscle area and quality. Hand grip correlated strongly with skeletal muscle area (correlation coefficient 0.64, p < 0.001) and mildly with ICT performance (0.34, p = 0.002). However, for women, the strongest correlation with hand grip was ICT performance (0.60, p < 0.001). Chair stand performance correlated best with SIP (correlation coefficient - 0.35, p < 0.001). MAMA was not correlated with CT-based muscle indices among women but was for men. Poor chair stand performance (< 10/30-s) had a sensitivity/specificity for falls of 73%/54%; low muscle radiation attenuation (density) was 40%/80% sensitive/specific.
CONCLUSION
Bedside measures of physical function, muscle bulk, and cognitive performance are correlated with CT-based muscle measures. Bedside measures of frailty may provide an advantage over sarcopenia for outcome assessment that should be confirmed prospectively.

Identifiants

pubmed: 31292783
doi: 10.1007/s10620-019-05713-4
pii: 10.1007/s10620-019-05713-4
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3652-3659

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR002241
Pays : United States

Références

Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–133.
doi: 10.1002/hep.29466
Su F, Yu L, Berry K, et al. Aging of liver transplant registrants and recipients: trends and impact on waitlist outcomes, post-transplantation outcomes, and transplant-related survival benefit. Gastroenterology. 2016;150:441.e6–453.e6.
doi: 10.1053/j.gastro.2015.10.043
Kanwal F, Tansel A, Kramer JR, et al. Trends in 30-day and 1-year mortality among patients hospitalized with cirrhosis from 2004 to 2013. Am J Gastroenterol. 2017;112:1287.
doi: 10.1038/ajg.2017.175
Kobashigawa J, Dadhania D, Bhorade S, et al. Report from the American Society of Transplantation on frailty in solid organ transplantation. Am J Transplant. 2019;19:984–994.
doi: 10.1111/ajt.15198
Lai JC, Covinsky KE, McCulloch CE, et al. The Liver Frailty Index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol. 2018;113:235.
doi: 10.1038/ajg.2017.443
Tapper EB, Finkelstein D, Mittleman MA, et al. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology. 2015;62:584–590.
doi: 10.1002/hep.27830
Lai JC, Sonnenday CJ, Tapper EB, et al. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am J Transplant. 2019;19:1896–1906.
pubmed: 30980701
Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010;211:271–278.
doi: 10.1016/j.jamcollsurg.2010.03.039
Carey EJ, Lai JC, Wang CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transplant. 2017;23:625–633.
doi: 10.1002/lt.24750
Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol. 2015;6:e102.
doi: 10.1038/ctg.2015.31
Laube R, Wang H, Park L, et al. Frailty in advanced liver disease. Liver Int. 2018;38:2117–2128.
doi: 10.1111/liv.13917
Force UPST. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med. 2004;140:554.
doi: 10.7326/0003-4819-140-7-200404060-00016
Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol Ser A Biomed Sci Med Sci. 2014;69:547–558.
doi: 10.1093/gerona/glu010
Lai JC, Covinsky KE, Dodge JL, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology. 2017;66:564–574.
doi: 10.1002/hep.29219
Frisancho AR. New standards of weight and body composition by frame size and height for assessment of nutritional status of adults and the elderly. Am J Clin Nutr. 1984;40:808–819.
doi: 10.1093/ajcn/40.4.808
Bajaj JS, Hafeezullah M, Franco J, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology. 2008;135:1591.e1–1600.e1.
doi: 10.1053/j.gastro.2008.07.021
Amodio P, Ridola L, Schiff S, et al. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology. 2010;139:510.e2–518.e2.
doi: 10.1053/j.gastro.2010.04.057
Nabi E, Thacker LR, Wade JB, et al. Diagnosis of covert hepatic encephalopathy without specialized tests. Clin Gastroenterol Hepatol. 2014;12:1384.e2–1389.e2.
doi: 10.1016/j.cgh.2013.12.020
Englesbe MJ, Lee JS, He K, et al. Analytic morphomics, core muscle size, and surgical outcomes. Ann Surg. 2012;256:255–261.
doi: 10.1097/SLA.0b013e31826028b1
Krishnamurthy V, Zhang P, Ethiraj S, et al. Use of analytic morphomics of liver, spleen, and body composition to identify patients at risk for cirrhosis. Clin Gastroenterol Hepatol. 2015;13:360.e5–368.e5.
doi: 10.1016/j.cgh.2014.07.042
Singal AG, Zhang P, Waljee AK, et al. Body composition features predict overall survival in patients with hepatocellular carcinoma. Clin Transl Gastroenterol. 2016;7:e172.
doi: 10.1038/ctg.2016.31
Derstine BA, Holcombe SA, Ross BE, et al. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep. 2018;8:11369.
doi: 10.1038/s41598-018-29825-5
Tapper EB, Konerman M, Murphy S, et al. Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index. Am J Transplant. 2018;18:2566–2570.
doi: 10.1111/ajt.15020
Ebadi M, Tandon P, Moctezuma-Velazquez C, et al. Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis. J Hepatol. 2018;69:608–616.
doi: 10.1016/j.jhep.2018.04.015
Tapper EB, Jiang ZG, Patwardhan VR. Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. Mayo Clin Proc. 2015;90:646–658.
doi: 10.1016/j.mayocp.2015.03.003
Wang CW, Feng S, Covinsky KE, et al. A comparison of muscle function, mass, and quality in liver transplant candidates: results from the Functional Assessment in Liver Transplantation (FrAILT) study. Transplantation. 2016;100:1692.
doi: 10.1097/TP.0000000000001232
Tapper EB, Parikh ND, Waljee AK, et al. Diagnosis of minimal hepatic encephalopathy: a systematic review of point-of-care diagnostic tests. Am J Gastroenterol. 2018;113:529–538.
doi: 10.1038/ajg.2018.6

Auteurs

Elliot B Tapper (EB)

Division of Gastroenterology and Hepatology, University of Michigan, 3912 Taubman, SPC 5362, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA. etapper@umich.edu.
Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. etapper@umich.edu.

Brian Derstine (B)

Morphomic Analysis Group, University of Michigan, Ann Arbor, MI, USA.

Jad Baki (J)

University of Michigan, Ann Arbor, MI, USA.

Grace L Su (GL)

Division of Gastroenterology and Hepatology, University of Michigan, 3912 Taubman, SPC 5362, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA.
Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH